PARIS, July 19 (Reuters) - France’s Ipsen has granted rights to an experimental diabetic drug to Swiss drugmaker Roche and has set foot in North America by buying a 25 percent stake in Tercica Inc. The agreements boosted Ipsen’s shares more than 3 percent and are in line with its aim to seek partners to help it launch and sell some of its drugs in the United States where its presence was limited to a research and development centre.
